Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE vs CARISOPRODOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis; caffeine is a central nervous system stimulant that antagonizes adenosine receptors.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Relief of discomfort associated with acute painful musculoskeletal conditions,Off-label: tension headache, migraine
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
1-2 tablets (orphenadrine citrate 50 mg, aspirin 770 mg, caffeine 60 mg per tablet) orally every 8-12 hours as needed; maximum 4 tablets per day.
250-350 mg orally 3 times daily and at bedtime
Orphenadrine: ~14 hours (range 12-16 h); Aspirin: 2-3 h for low doses, 15-30 h for high/anti-inflammatory doses due to saturable metabolism; Caffeine: 3-6 h in adults, prolonged in liver disease.
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Orphenadrine: hepatic N-demethylation and hydroxylation via CYP450 enzymes; Aspirin: hydrolysis to salicylate and conjugation with glycine and glucuronic acid; Caffeine: hepatic metabolism via CYP1A2.
Primarily hepatic via CYP2C19; partially metabolized to meprobamate (a Schedule IV controlled substance) by N-dealkylation; also undergoes hydrolysis and subsequent conjugation.
Orphenadrine: ~60% renal (metabolites, <8% unchanged), ~20% biliary/fecal; Aspirin: ~80-100% renal (salicylates, dose-dependent; alkaline urine increases excretion); Caffeine: ~1-3% renal (unchanged), main metabolites renal.
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
Orphenadrine: ~30% (albumin); Aspirin: 80-90% (albumin, saturable); Caffeine: 25-36% (albumin).
Carisoprodol: approximately 60% bound to plasma proteins (predominantly albumin). Meprobamate: ~20% bound.
Orphenadrine: ~2.5 L/kg (widespread, CNS penetration); Aspirin: 0.15-0.2 L/kg (low, primarily extracellular); Caffeine: 0.6-0.8 L/kg.
Apparent Vd: approximately 0.8 L/kg for carisoprodol (total body water distribution). Clinical meaning: Extensive distribution into tissues; consistent with moderate lipophilicity.
Oral: Orphenadrine ~90%; Aspirin 40-50% (first-pass hydrolysis to salicylate); Caffeine ~100%.
Oral: Approximately 95% absorbed from the GI tract; extensive first-pass metabolism converts ~50% to meprobamate; net bioavailability of parent drug is ~50-60%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-59 m L/min), extend dosing interval to every 12-24 hours. No adjustment for mild impairment (Cr Cl 60-89 m L/min).
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
Contraindicated in Child-Pugh class C. For Child-Pugh class B, reduce dose by 50% or extend interval to every 12-24 hours. Use with caution in Child-Pugh class A.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not recommended for pediatric use due to aspirin's association with Reye's syndrome and lack of safety data for orphenadrine in children.
Not recommended for use in children under 16 years due to lack of safety and efficacy data.
Use lower end of dosing range (e.g., 1 tablet every 12 hours) due to increased sensitivity to anticholinergic effects and risk of aspirin-induced gastrointestinal bleeding. Avoid use in patients >80 years if possible.
Initiate at 250 mg 3-4 times daily; monitor for sedation and falls; consider reducing dose in frail elderly.
No FDA black box warning.
None
Avoid in patients with glaucoma, prostatic hypertrophy, or urinary retention due to anticholinergic effects; caution in elderly and those with cardiovascular disease; risk of GI bleeding with aspirin; limit caffeine intake to avoid excessive stimulation.
Risk of sedation and dizziness, impairing ability to drive or operate machinery,Potential for abuse and dependence, especially with long-term use; meprobamate is a controlled substance,Withdrawal symptoms including anxiety, insomnia, and seizures upon abrupt discontinuation,Hepatic impairment may alter metabolism; use with caution,May cause serotonin syndrome when used with other serotonergic drugs,Respiratory depression with concurrent use of CNS depressants
Hypersensitivity to any component; patients with angle-closure glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcer, prostatic hypertrophy, or bladder neck obstruction; severe renal or hepatic impairment; bleeding disorders; concurrent use of anticoagulants.
Hypersensitivity to carisoprodol or meprobamate,Acute intermittent porphyria,Concomitant use with MAOIs (potential for hypertensive crisis)
Avoid high-tyramine foods (e.g., aged cheeses, cured meats) due to orphenadrine's anticholinergic effects on gut motility. Evening meals high in caffeine may worsen insomnia. Aspirin absorption is delayed by food, but taking with food reduces GI irritation.
Avoid alcohol. No specific food interactions known, but CNS depressant effects may be exacerbated by alcohol or other sedating substances.
First trimester: Aspirin is associated with increased risk of gastroschisis (ORS 1.5-2.0) and possibly cardiac defects; orphenadrine and caffeine have limited data but caffeine may increase miscarriage risk. Second trimester: Aspirin at high doses may impair fetal renal function; orphenadrine and caffeine effects are not well-studied. Third trimester: Aspirin use after 30 weeks gestation increases risk of premature closure of ductus arteriosus and oligohydramnios; orphenadrine may cause neonatal withdrawal; caffeine may accumulate.
Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: Limited data suggest a possible increased risk of congenital anomalies, particularly with first-trimester exposure. Second and third trimesters: Use may be associated with neonatal withdrawal syndrome including irritability, tremors, and poor feeding. Avoid use during pregnancy, especially during the first trimester.
Aspirin and its metabolites are excreted into breast milk (M/P ratio ~0.04-0.27 for salicylate); orphenadrine is not known to be excreted; caffeine is excreted (M/P ratio ~0.5-0.76). Theoretical risk of Reye's syndrome with aspirin, and irritability in infant with caffeine. Use caution, avoid high doses.
Carisoprodol and its active metabolite meprobamate are excreted into human breast milk. The milk-to-plasma ratio (M/P) is not well established but considered low. However, potential adverse effects in nursing infants include sedation and withdrawal symptoms. The manufacturer recommends caution; avoid breastfeeding while using carisoprodol due to risk of neonatal sedation.
No specific pharmacokinetic studies for the combination; however, pregnancy increases renal clearance of aspirin, requiring dose adjustments for anti-inflammatory effect. Caffeine clearance decreases in later pregnancy; orphenadrine metabolism may be altered but data insufficient. Use lowest effective dose for shortest duration.
Pharmacokinetic changes during pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce carisoprodol concentrations. However, no specific dose adjustments are recommended due to lack of data and potential fetal risks. Use is not recommended in pregnancy; therefore, dose adjustments are not applicable.
Orphenadrine citrate has anticholinergic properties; use cautiously in patients with glaucoma, urinary retention, or myasthenia gravis. Aspirin component increases bleeding risk, especially with concurrent anticoagulants. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of salicylism with high doses or hepatic impairment.
Carisoprodol is centrally acting muscle relaxant that is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with history of substance abuse. Use short-term (2-3 weeks) due to lack of evidence for long-term efficacy. Monitor for sedation and dizziness; avoid concomitant use with other CNS depressants. Taper to discontinue after prolonged use to prevent withdrawal symptoms.
Take with food to reduce gastrointestinal upset.,Avoid alcohol while taking this medication.,Do not exceed recommended dosage; may cause dizziness or drowsiness.,Discontinue and seek medical attention if you experience signs of bleeding (e.g., black stools) or allergic reaction.,Inform your doctor if you have a history of stomach ulcers, bleeding disorders, or asthma.
Take only as prescribed for short-term relief (usually 2-3 weeks).,Do not increase dose or stop abruptly without consulting doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other sedatives while taking this medication.,Report any signs of abuse or dependence (e.g., craving, needing higher doses).,Do not share this medication with others due to abuse potential.,Seek medical attention if you experience allergic reactions (rash, itching, swelling) or seizures.
"Orphenadrine, a centrally acting muscle relaxant with sedative and anticholinergic properties, can potentiate the central nervous system (CNS) depressant effects of Ketazolam, a benzodiazepine anxiolytic. This synergistic pharmacodynamic interaction leads to enhanced sedation, impaired cognitive function, and increased risk of falls or respiratory depression, particularly in elderly or debilitated patients. The combination may also exacerbate anticholinergic side effects such as confusion and urinary retention."
"Orphenadrine, a centrally acting muscle relaxant with anticholinergic properties, may enhance the central nervous system depressant effects of lithium cation, an antimanic agent. This additive pharmacodynamic interaction can lead to increased sedation, dizziness, and confusion, potentially impairing cognitive and motor function. Clinically, patients may experience exacerbated lithium-induced neurotoxicity, manifesting as tremor, ataxia, or altered mental status, particularly in elderly or renally impaired individuals."
"Orphenadrine, a centrally acting muscle relaxant with anticholinergic properties, can potentiate the central nervous system (CNS) depressant effects of ethylmorphine, an opioid analgesic. This additive pharmacodynamic interaction may lead to enhanced sedation, respiratory depression, and psychomotor impairment, increasing the risk of falls, cognitive dysfunction, and potentially fatal respiratory compromise, particularly in elderly or debilitated patients."
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE vs CARISOPRODOL, answered by our medical review team.
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is a Skeletal Muscle Relaxant that works by Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis; caffeine is a central nervous system stimulant that antagonizes adenosine receptors.. CARISOPRODOL is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE and CARISOPRODOL depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is: 1-2 tablets (orphenadrine citrate 50 mg, aspirin 770 mg, caffeine 60 mg per tablet) orally every 8-12 hours as needed; maximum 4 tablets per day.. The standard adult dose of CARISOPRODOL is: 250-350 mg orally 3 times daily and at bedtime. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE and CARISOPRODOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is classified as Category A/B. First trimester: Aspirin is associated with increased risk of gastroschisis (ORS 1.5-2.0) and possibly cardiac defects; orphenadrine and caffeine have limited data but caffeine may. CARISOPRODOL is classified as Category A/B. Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.